Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

Novel cancer immunotherapy for dogs could benefit humans as well

Novel cancer immunotherapy for dogs could benefit humans as well

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

Patients with advanced colorectal cancer respond well to new combination therapy

Patients with advanced colorectal cancer respond well to new combination therapy

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014